FDA-Approved Non-Small Cell Lung Cancer (NSCLC) Treatments

Share this content:
FDA-APPROVED NON-SMALL CELL LUNG CANCER (NSCLC) TREATMENTS
Generic Brand Strength Form Usual Dose
Angiogenesis inhibitor
bevaci-
zumab
Avastin 100mg, 
400mg
soln for IV infusion after
dilution
15mg/kg once every 3wks with
carboplatin/paclitaxel
ramuci-
rumab
Cyramza 10mg/mL soln for IV infusion after
dilution
10mg/kg on Day 1 of a 21‑day
cycle prior to docetaxel;
continue until disease progres-
sion or unacceptable toxicity
Antimetabolites
gemcitabine Gemzar 200mg, 1g pwd for IV infusion after
reconstitution
1000mg/m² on Days 1, 8, and
15 of each 28 day cycle; or
1250mg/m² on Days 1 and 8
of each 21 day cycle
metho-
trexate
25mg/mL soln for IV, IM, intra-
arterial, or intrathecal
administration after
dilution
See drug monograph and manufacturer's full labeling
1g pwd for IV, IM, intra-
arterial, or intrathecal
administration after
dilution
Trexall 5mg, 7.5mg, 10mg, 15mg scored tabs
pemetrexed Alimta 100mg, 500mg pwd for IV inj after
reconstitution and
dilution
500mg/m² on Day 1 of each
21‑day cycle
Antimicrotubule agents
docetaxel Taxotere 40mg/mL soln for IV infusion after
dilution
75mg/m² once every 3wks
paclitaxel Taxol 6mg/mL soln for IV infusion after
dilution
135mg/m² IV plus cisplatin
every 3wks
paclitaxel [bound to albumin 
(human)]
Abraxane 100mg/
 
vial
pwd for IV infusion after
reconstitution
100mg/m² on Days 1, 8, and
15 of each 21‑day cycle
vinorelbine Navelbine 10mg/mL soln for IV inj after
dilution
Monotherapy: 30mg/m² once
weekly
Combination therapy: 25mg/m²
once weekly given every 4wks;
or 30mg/m² once weekly given
on Days 1 and 29, then every
6wks
HUMAN EGFR INHIBITOR
necitumumab Portrazza 800mg/50mL soln for IV infusion after dilution 800mg on Days 1 and 8 of each 21-day cycle; continue until disease progression or unacceptable toxicity
PD-1 Blocking Antibody
nivolumab Opdivo 10mg/mL soln for IV infusion after
dilution
3mg/kg every 2wks until disease
progression or unacceptable toxicity
pembrolizumab Keytruda 50mg/vial pwd for IV infusion after
reconstitution
200mg every 3wks until disease progression or unacceptable toxicity; or up to 24mos in patients without disease progression
25mg/mL soln for IV infusion after
dilution
Photosensitizing agent
porfimer Photofrin 75mg pwd for IV inj after
reconstitution
2mg/kg then illumination with
laser light 40−50hrs following
injection
Tyrosine Kinase Inhibitors
afatinib Gilotrif 20mg, 30mg, 40mg tabs 40mg once daily on empty stomach; continue until disease progression or unacceptable toxicity
alectinib Alecensa 150mg caps 600mg twice daily until disease
progression or unacceptable
toxicity
ceritinib Zykadia 150mg hard gel caps 750mg once daily until disease
progression or unacceptable
toxicity
crizotinib Xalkori 200mg, 250mg caps 250mg twice daily until disease progression or unacceptable toxicity
erlotinib Tarceva 25mg, 100mg, 150mg tabs 150mg once daily
gefitinib Iressa* 250mg tabs 250mg once daily until disease progression or unacceptable toxicity
osimertinib Tagrisso 40mg, 80mg tabs 80mg once daily until disease progression or unacceptable toxicity
NOTES

*For NSCLC with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations only.

For metastatic NSCLC with EGFR T790M mutation only.
Not an inclusive list of medications, official indications, and/or dosing details. Please see drug monograph at www.eMPR.com and/or contact company for full drug labeling.

(Rev. 1/2017)

Sign Up for Free e-newsletters